BAD Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-mediated gene-disrupted pool of near-haploid human HAP1 cells, engineered to eliminate expression of the pro-apoptotic BCL-2 family member BAD. This polyclonal knockout population provides a mixed genetic background of loss-of-function alleles, enabling robust functional studies without the bottleneck of single-cell cloning. The product is supplied as a population of knockout cells that have undergone antibiotic selection and pooled expansion, suitable for direct culture and experimental use. This model allows researchers to interrogate BAD-dependent apoptosis and survival signaling in a genetically simplified host background.
The HAP1 cell line is a near-haploid, adherent, fibroblast-like line originally derived from the KBM-7 chronic myeloid leukemia isolate. Its near-haploid karyotype facilitates genetic manipulations and makes it an ideal platform for loss-of-function screens, as only a single allele requires disruption to generate a null phenotype. HAP1 cells retain key features of the myeloid lineage and are widely used in high-throughput drug-sensitivity profiling, synthetic lethality screens, and CRISPR-based genetic interaction mapping. The cells are cultured in standard adherent conditions and exhibit robust growth, which supports large-scale screening campaigns and reproducible biochemical assays.
BAD (BCL2 associated agonist of cell death) is a BH3-only protein that operates as a sentinel at the intersection of pro-survival and pro-death signals. In the absence of trophic factors, unphosphorylated BAD translocates to the mitochondrial outer membrane, where it binds and inhibits anti-apoptotic BCL-2 and BCL-XL. This interaction liberates BAX and BAK to oligomerize, inducing mitochondrial outer membrane permeabilization, cytochrome c release, and subsequent caspase-9 and caspase-3 activation. Survival signaling via receptor tyrosine kinases such as EGF and PDGF triggers the PI3K/AKT pathway; AKT directly phosphorylates BAD at Ser136, creating a binding motif for 14-3-3 scaffold proteins that sequester BAD in the cytosol. Additional kinases, including PKA and RSK, phosphorylate BAD at other residues, while phosphatases like PP2A reverse these modifications. BAD also interacts with RAF-1, linking growth factor signaling to apoptosis regulation. JAK/STAT and Ras/MAPK pathways converge on BAD phosphorylation, fine-tuning the apoptotic threshold. Thus, BAD functions as a critical node where multiple signaling cascades integrate to determine cell fate.
In the HAP1 cellular context, disruption of BAD removes a key pro-apoptotic constraint, creating a background in which mitochondrial apoptosis is impaired. This enables dissecting the contribution of BAD to stress-induced cell death, particularly under conditions of growth factor deprivation, chemotherapeutic challenge, or oxidative stress. The near-haploid nature of HAP1 accentuates the phenotypic consequences of single-gene disruptions, making the knockout model highly penetrant. Researchers can use these cells to map genetic interactions between BAD and other apoptotic regulators, such as BCL-2 family members or components of the PI3K/AKT axis, without confounding effects from duplicated alleles. The model also supports investigation of BAD-independent cell death pathways, providing a clean comparator for pharmacological and genetic perturbations.
BAD Knockout HAP1 Polyclonal Cells are suited for a range of experimental applications in apoptosis research, drug discovery, and signal transduction studies. The cells can be employed in high-throughput screens to identify small-molecule modulators of cell death that bypass BAD, or to validate hits that restore apoptosis in BAD-deficient backgrounds. Representative assays include Western blotting for total BAD and phospho-BAD (e.g., Ser136), annexin V staining and flow cytometry to quantify apoptosis, caspase-3/7 activity luminescence assays, co-immunoprecipitation of remaining BCL-2 family complexes, and JC-1 staining for mitochondrial membrane potential. Cell viability assays (MTT or CellTiter-Glo) under stress conditions??such as staurosporine treatment, serum withdrawal, or etoposide exposure??can delineate BAD-dependent vs. independent death mechanisms. The polyclonal nature of the knockout population supports scalable experiments while maintaining genetic heterogeneity, which may better reflect physiological variation. For further technical details or to discuss your specific application, please contact Ascent Research.
